Design Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Design Therapeutics, Inc. (DSGN) had Debt Securities, Available-for-sale, Unrealized Loss Position of $154.48 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-03
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $154.48M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $132.48M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $9.99M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $32.40M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $154.48M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $132.48M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $9.99M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $32.40M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $74.55M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $59.52M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $27.99M 10-K · filed 2026-03-09 |
| 2024-09-30 | $21.21M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $183.72M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $174.72M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $126.25M 10-K · filed 2025-03-10 |
| 2023-09-30 | $258.01M 10-Q · filed 2023-11-13 |
| 2022-12-31 | $284.26M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |